Navigation Links
Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
Date:6/15/2009

AURORA, Ontario, June 15 /PRNewswire/ -- Helix BioPharma Corp. ("Helix" or the "Company"), (TSX, FSE: "HBP") today announced its product development progress, quarterly highlights and financial results for the third quarter of fiscal 2009, ended April 30, 2009.

THIRD QUARTER HIGHLIGHTS AND PRODUCT DEVELOPMENT UPDATE

U.S. Registration Statement

Helix's 20-F registration statement filed with the U.S. Securities and Exchange Commission became effective during the quarter.

BioFinance 2009 Investor Conference Presentation

John Docherty, president and chief operating officer, presented at the BioFinance 2009 Investor Conference, where he provided an overview of the Company's leading technology platforms, DOS47(TM) and Biphasix(TM) and the Company's current product development programs, L-DOS47 and Topical Interferon Alpha-2b.

L-DOS47 Product Development Update

Over the past quarter, Helix has continued to advance towards initiating Phase I/II-level human clinical studies with L-DOS47. It has submitted a formal meeting request to the FDA for a pre-IND meeting, in anticipation of a future IND filing. The Company has also continued to advance its GMP manufacturing scale-up program with the successful production of engineering batches of L-DOS47, and is currently making preparations to produce its first clinical batch of GMP product to be used in its initial human trials.

Helix plans to file IND/CTA applications in North America and Europe, respectively, to seek permission to initiate Phase I/II studies. Due to recent challenges in successfully producing GMP engineering batches to date, including third party scheduling and technical issues, the Company has revised its estimated date of IND filing. Based on the estimated delay for completing the remaining program activities, and assuming successful and timely completi
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IL (PRWEB) January 15, 2014 Look ... find hard-working items for the lab, from fluid handling ... Guaranteed-in-Stock (GIS)—ready to ship when you order. , ... Peristaltic Pumps , from the L/S® model for precise ...
(Date:1/15/2014)... This webinar will focus on EMA ... assessment in biosimilars. , Regulatory frameworks are evolving many ... however the complex nature of biopharmaceuticals makes the demonstration ... extremely challenging. Based on the specific aspects of biosimilar ...
(Date:1/15/2014)... January 15, 2014 The Microcompetition with Foreign ... disease. One of these latent viruses is the Epstein Barr ... (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that ... study found that RA patients have high concentrations of EBV ...
(Date:1/15/2014)... January 15, 2014 AudioNotch is the ... therapy for the treatment of tinnitus. Patients listen to ... and over a period of weeks to months, their tinnitus ... in two forms: Notched Music and Notched White Noise. Now, ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... expanded access to choice, quality and cost-efficiency for patients ... Fla., June 24 Galichia Heart Hospital and Mobile ... to host MSI-coordinated, highly specialized, urologic surgical teams at ... Galichia,s capabilities as a center of excellence for selected ...
... 24 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... company focused on endocrine therapy and oncology, announced ... registered direct offering of US$10 million of units ... warrants to certain institutional investors. AEterna Zentaris received ...
... and diagnostics, including new technologies, enhanced biotech and drug developments, ... the center of Cleveland Clinic,s 7th Annual Medical Innovation Summit, ... more than 900 leaders from throughout the healthcare industry to ... and gain actionable insights. , , This year,s ...
Cached Biology Technology:Galichia Heart Hospital Partners with Mobile Surgery International to Develop Wichita-based Center of Excellence with Global Convenience(TM) 2Galichia Heart Hospital Partners with Mobile Surgery International to Develop Wichita-based Center of Excellence with Global Convenience(TM) 3AEterna Zentaris Receives US$10 Million from Institutional Investors 2AEterna Zentaris Receives US$10 Million from Institutional Investors 32009 Medical Innovation Summit at Cleveland Clinic to Highlight the Latest Developments in Cancer Care 22009 Medical Innovation Summit at Cleveland Clinic to Highlight the Latest Developments in Cancer Care 3
(Date:4/24/2014)... America (ESA) is very pleased to announce that it ... Science from the University of Wisconsin. , The ... an international, open-access, peer-reviewed journal that publishes papers on ... arthropods -- from the molecular to the ecological -- ... is freely available to individuals and institutions, and it ...
(Date:4/24/2014)... Researchers from North Carolina State University and the University ... new ultrasound device that could help identify arterial plaque ... causing heart attack or stroke. , At issue is ... age. Some types of plaque are deemed "vulnerable," meaning ... artery wall and cause heart attack or stroke. , ...
(Date:4/24/2014)... WASHINGTON, April 24A droplet of clear liquid can bend ... well-known phenomenon, researchers have developed a new process to ... than a penny apiece. , Because they,re so ... of applications, including tools to detect diseases in the ... and microscopes for education in classrooms. , "What ...
Breaking Biology News(10 mins):ESA to publish the Journal of Insect Science 2New ultrasound device may add in detecting risk for heart attack, stroke 2Bake your own droplet lens 2Bake your own droplet lens 3
... especially in intensive production. Piglets commonly become susceptible to ... to losses of 10% or more. The antibiotics used ... have now fallen out of use, mainly due to ... A radical solution has been found by using a ...
... cushy haploid environs to take up residence in a ... but Indiana University Bloomington scientists report in this week's ... plants. , "Plants that reproduce clonally or are ... mitochondrion to the nucleus," said graduate student Yaniv Brandvain, ...
... that help shape our understanding of how tool use ... chimpanzees, at least under some conditions, are capable of ... The work, reported by Jill Pruetz of Iowa State ... will appear online in the journal Current Biology on ...
Cached Biology News:A healthier start to a pig's life 2Mitochondrial genes move to the nucleus -- but it's not for the sex 2Chimpanzees found to use tools to hunt mammalian prey 2